1.
AIDS
; 34(5): 789-790, 2020 04 01.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31895147
RESUMO
: Integrase strand transfer inhibitor-based antiretroviral therapy can cause weight gain. It is unknown if this is a class effect, with limited data regarding raltegravir. In 37 virologically suppressed adults (36 men, mean age 49 years) who switched from tenofovir disoproxil fumarate to raltegravir 400âmg twice daily, mean weight changes from baseline at weeks 24, 48 and 96 were not significant (maximum 0.8âkg at week 24; all Pâ≥â0.16). Weight gain may not occur with all integrase strand transfer inhibitors.